Novel blood lipid lowering composition

A composition and a blood lipid-lowering technology, applied in the field of medicine, can solve problems such as unsatisfactory treatment effect and the like

Inactive Publication Date: 2011-11-23
FUKANGREN BIO PHARMA
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, a variety of blood lipid-lowering drugs have been launched one after another, which has increased the safety of patients with hyperlipidemia, b

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel blood lipid lowering composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Embodiment 1: tablet

[0015] Name of raw material

1

2

3

4

5

Alikren Fumarate

150g

150g

150g

150g

150g

Atorvastatin

5g

----

----

----

----

Fenofibrate

----

100g

----

----

100g

Niacin

----

----

250g

375g

500g

Simvastatin

----

----

----

10g

----

microcrystalline cellulose

85g

80g

45g

65g

75g

lactose

36g

36g

36g

36g

36g

Sodium carboxymethyl cellulose

10g

10g

10g

10g

10g

5% PVP K30 solution

Appropriate amount

Appropriate amount

Appropriate amount

Appropriate amount

Appropriate amount

Magnesium stearate

1.6g

1.6g

1.6g

1.6g

1.6g

[0016] Note: Aliklen fumarate specifications ar...

Embodiment 2

[0018] Embodiment 2: Sustained-release tablet

[0019] Name of raw material

1

2

3

Alikren Fumarate

150g

150g

150g

Atorvastatin

----

----

----

Fenofibrate

----

----

100g

Niacin

250g

375g

500g

Simvastatin

----

10g

----

Hypromellose E10M

101.5g

185g

203g

PVP K90

8.75g

105g

17.5g

Sodium carboxymethyl cellulose

10g

10g

10g

microcrystalline cellulose

56g

56g

56g

lactose

45g

45g

45g

stearic acid

1.6g

1.6g

1.6g

purified water

Appropriate amount

Appropriate amount

Appropriate amount

[0020] Note: Aliklen fumarate specification is calculated by Aliklen, levamlodipine besylate is calculated by amlodipine

[0021] Process: take each raw material, crush and pass thr...

Embodiment 3

[0022] Embodiment 3: lipid-lowering effect experiment

[0023] Male Wistar rats (grade 2), weighing 160-170 g. Give high-fat diet 25g (high-fat feed formula: basal feed: cholesterol: lard: cholate: methylthiouracil = 8418: 4: 10: 1: 012) in a quantitative manner every day for 26 days, and the establishment of hyperlipidemia mouse model.

[0024] In addition to a blank control group (0) that was not given high-fat feed, the experimental animals that successfully established the model were randomly divided into model group (A), simvastatin (B1), aliskiren + simvastatin (B2), fenofibrate (C1), aliskiren + fenofibrate (C2), niacin (D1), aliskiren + niacin (D2), aliskiren + niacin + simvastatin (E), Aliskiren + fenofibrate + simvastatin (F), Aliskiren + niacin + fenofibrate group (G), etc. All the drugs were suspended in 0.5% sodium carboxymethylcellulose and administered by intragastric administration once a day for 10 consecutive days. After 10 days, blood was collected from ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a novel blood lipid lowering composition, which is a medicinal composition comprising aliskiren and a medicinal salt thereof, a hydrate and 1-2 of statin, fibrate and nicotinic acid lipid lowering medicaments, serving as active ingredients. The composition can be prepared into oral tablets or capsules for treating hyperlipidemia; and the curative effect of the composition is superior to that of the conventional common lipid lowering medicament.

Description

technical field [0001] The invention relates to a novel blood fat-lowering composition, which belongs to the technical field of medicine. Background technique [0002] Hyperlipidemia refers to high cholesterol (TC) and / or triglyceride (TG) or low high-density lipoprotein cholesterol (HDL-C) in the blood. The damage to the body of the disease is hidden, gradual, progressive and systemic. sexual. Its direct damage is to accelerate systemic atherosclerosis, because vital organs of the whole body rely on arterial blood supply and oxygen supply. Once the arteries are blocked by atherosclerotic plaques, serious consequences will result. Renal failure caused by arteriosclerosis is closely related to hyperlipidemia. A large number of research data show that hyperlipidemia is an independent and important risk factor for stroke, coronary heart disease, myocardial infarction, and sudden cardiac death. In recent years, a variety of blood lipid-lowering drugs have been launched one af...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/165A61K31/40A61K31/22A61K31/405A61K31/505A61K31/47A61K31/366A61K31/216A61K31/192A61K31/455A61K31/4965A61K31/44A61K31/444A61K31/475A61P3/06
Inventor 不公告发明人
Owner FUKANGREN BIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products